Free Trial

State of Wyoming Decreases Position in Henry Schein, Inc. (NASDAQ:HSIC)

Henry Schein logo with Medical background

State of Wyoming cut its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 51.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,715 shares of the company's stock after selling 3,873 shares during the quarter. State of Wyoming's holdings in Henry Schein were worth $257,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Smartleaf Asset Management LLC raised its holdings in Henry Schein by 23.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock worth $52,000 after purchasing an additional 143 shares during the last quarter. Guggenheim Capital LLC increased its position in shares of Henry Schein by 2.5% during the fourth quarter. Guggenheim Capital LLC now owns 6,428 shares of the company's stock worth $445,000 after buying an additional 159 shares during the period. CIBC Asset Management Inc raised its stake in Henry Schein by 1.0% during the fourth quarter. CIBC Asset Management Inc now owns 17,849 shares of the company's stock worth $1,235,000 after buying an additional 169 shares during the last quarter. Metis Global Partners LLC lifted its holdings in Henry Schein by 4.7% in the fourth quarter. Metis Global Partners LLC now owns 4,203 shares of the company's stock valued at $291,000 after buying an additional 187 shares during the period. Finally, Sanctuary Advisors LLC boosted its position in Henry Schein by 5.0% during the fourth quarter. Sanctuary Advisors LLC now owns 4,253 shares of the company's stock valued at $294,000 after acquiring an additional 203 shares during the last quarter. Institutional investors own 96.62% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. UBS Group dropped their target price on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 26th. Piper Sandler cut their price objective on shares of Henry Schein from $83.00 to $77.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 30th. Wall Street Zen downgraded Henry Schein from a "buy" rating to a "hold" rating in a research note on Thursday, April 17th. Barrington Research decreased their target price on Henry Schein from $90.00 to $86.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Finally, Wells Fargo & Company cut their price target on Henry Schein from $80.00 to $75.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Six research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $79.30.

Get Our Latest Analysis on Henry Schein

Henry Schein Price Performance

NASDAQ:HSIC traded down $0.26 during trading hours on Wednesday, hitting $73.40. The stock had a trading volume of 1,299,605 shares, compared to its average volume of 1,661,710. The company has a 50 day simple moving average of $67.54 and a two-hundred day simple moving average of $71.58. The firm has a market capitalization of $8.93 billion, a price-to-earnings ratio of 30.21, a P/E/G ratio of 2.13 and a beta of 0.87. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. Henry Schein, Inc. has a one year low of $60.56 and a one year high of $82.49.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.11 by $0.04. The business had revenue of $3.17 billion during the quarter, compared to analysts' expectations of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm's revenue was down .1% on a year-over-year basis. During the same period in the previous year, the business earned $1.10 earnings per share. Research analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Insider Activity at Henry Schein

In other news, Director Philip A. Laskawy sold 2,604 shares of the firm's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total transaction of $184,988.16. Following the sale, the director now owns 24,805 shares in the company, valued at approximately $1,762,147.20. This trade represents a 9.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the transaction, the chief executive officer now directly owns 62,688 shares in the company, valued at approximately $4,460,251.20. This represents a 6.05% decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by insiders.

Henry Schein Profile

(Free Report)

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

See Also

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Should You Invest $1,000 in Henry Schein Right Now?

Before you consider Henry Schein, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Henry Schein wasn't on the list.

While Henry Schein currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines